GleamWall
中文EN

XTLB XTL BIOPHARMACEUTICALS LTD IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1023549

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY42.4%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin0.7%
Operating margin-481.6%
Net margin-227.7%
FCF margin-370.7%
EBITDA margin—

Returns

ROE-26.8%
ROA-18.7%
ROIC (approx.)-58.3%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets36.4%
Debt / equity0.00x
Current ratio0.61x
Interest coverage-77.57x

Cash quality & payout

Operating cash flow / net income1.58x
Accruals ratio10.8%
Payout ratio—
Capex / revenue12.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2022Q2*2022-06-302021Q2*2021-06-302020Q2*2020-06-30
Income statement
Revenue———
R&D expense$15,000$6,000$11,000
SG&A expense$187,000$297,000$206,000
Operating income-$202,000-$303,000-$217,000
Net income-$285,000-$1.15M-$1.10M
EPS (basic)-0.00-0.00—
EPS (diluted)-0.00-0.00—
Weighted avg. shares (diluted)544.91M527.79M—
Balance sheet
Cash & equivalents$2.35M$2.92M$4.03M
Short-term investments$2.81M$3.38M—
Current assets$5.38M$6.57M—
Intangibles$380,000$380,000—
Total assets$5.76M$6.95M—
Total liabilities$194,000$3.67M—
Shareholders' equity$5.56M$3.28M$5.59M
Shares outstanding544.91M528.16M—
Cash flow statement
Operating cash flow———

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.